Abstract
The HeartMate 3TM (HM3) Left Ventricular Assist Device (LVAD) is the most recent LVAD to receive CE mark and FDA approval. It is a fully magnetically levitated pump with no reported haemolysis, pump thrombosis or pump failure in the first-in-man study [ [1] Zimpfer D. Netuka I. Schmitto J.D. Pya Y. Garbade J. Morshuis M. et al. Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes. Eur J Cardiothorac Surg. 2016; 50: 548-554 Crossref PubMed Scopus (27) Google Scholar ]. It has now received market approval in the European Union, the United States of America and Australia. We reviewed our real life experience with the device, to assess outcomes over the medium term.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
